Fenebrutinib - Genentech
Alternative Names: GDC-0853; RG-7845; RO-7010939Latest Information Update: 06 Sep 2024
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech
- Class Antineoplastics; Antirheumatics; Piperazines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- No development reported Autoimmune disorders
- Discontinued Chronic lymphocytic leukaemia; Chronic urticaria; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 05 Sep 2024 Adverse events and efficacy data from phase III FENopta trial in Multiple sclerosis released by Roche
- 07 May 2024 Roche plans a phase I bioequivalence trial in the UK (PO) in June 2024 (ISRCTN23183841)
- 13 Apr 2024 Adverse events and efficacy data from phase III FENopta trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)